Research progress of immune checkpoint inhibitors in ovarian cancer DOI Creative Commons

Lingli Zhao,

Yanhong Zhai,

Gaoli Niu

и другие.

Exploration of Immunology, Год журнала: 2024, Номер unknown, С. 853 - 870

Опубликована: Дек. 18, 2024

Ovarian cancer is the deadliest malignant tumor in female reproductive system. Despite advancements standard treatments such as debulking surgery and platinum-based chemotherapy, overall survival rate remains low. The emergence of targeted therapies, including Poly(ADP-ribose) polymerase (PARP) inhibitors anti-angiogenic agents, has provided new avenues for treatment. However, drug resistance disease heterogeneity continue to pose significant challenges. Immune checkpoint (ICIs), an emerging therapeutic approach, primarily target programmed cell death protein 1 (PD-1)/programmed ligand (PD-L1) cytotoxic T-lymphocyte antigen 4 (CTLA-4) pathways restore anti-tumor immune responses. Although ICIs have shown efficacy other malignancies, their effectiveness ovarian limited, with a response only 10–15% monotherapy. Recent studies focused on combining or PARP enhance outcomes. This article reviews progress cancer, monotherapy combination treatment strategies, explores targets strategies aimed at improving patient prognosis achieving personalized By gaining deeper understanding microenvironment its evasion mechanisms, there hope developing more effective options future, ultimately rates quality life patients.

Язык: Английский

Fungi, immunosenescence and cancer DOI Creative Commons
Bin Xu,

Zan Luo,

Xing Niu

и другие.

Seminars in Cancer Biology, Год журнала: 2025, Номер 109, С. 67 - 82

Опубликована: Янв. 7, 2025

Язык: Английский

Процитировано

4
CD8+ T cell exhaustion in the tumor microenvironment of breast cancer DOI Creative Commons

Hanghang Xie,

Xiaowei Xi, Ting Lei

и другие.

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Дек. 9, 2024

CD8+ T cells are crucial cytotoxic components of the tumor immune system. In chronic inflammation, they become low-responsive, a state known as cell exhaustion (TEX). The aim checkpoint blockade is to counteract TEX, yet its dynamics in breast cancer remain poorly understood. This review defines TEX and outlines features underlying mechanisms. It also discusses primary mechanisms cancer, covering inhibitory receptors, immunosuppressive cells, cytokines, transcriptomic epigenetic alterations, metabolic reprogramming, exosome pathways, offering insights into potential immunotherapy strategies for cancer.

Язык: Английский

Процитировано

12
Combined targeting of senescent cells and senescent macrophages: A new idea for integrated treatment of lung cancer DOI
Ming Gu, Yang Liu, Wenhui Zheng

и другие.

Seminars in Cancer Biology, Год журнала: 2024, Номер 106-107, С. 43 - 57

Опубликована: Авг. 29, 2024

Язык: Английский

Процитировано

11
Drivers of centrosome abnormalities: senescence progression and tumor immune escape DOI
Tao Jiang,

Hua Jin,

Xintong Ji

и другие.

Seminars in Cancer Biology, Год журнала: 2025, Номер unknown

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

0
Reshaping the immune microenvironment and reversing immunosenescence by natural products: prospects for immunotherapy in gastric cancer DOI
Zhipeng Cao, Zhilin Wang, Yang Li

и другие.

Seminars in Cancer Biology, Год журнала: 2025, Номер 110, С. 1 - 16

Опубликована: Фев. 8, 2025

Язык: Английский

Процитировано

0
Prognostic Significance of CDK1 in Ovarian and Cervical Cancers DOI Creative Commons
Xu Cong, Chao‐Wen Chen, Yonghong Xu

и другие.

Journal of Cancer, Год журнала: 2025, Номер 16(5), С. 1656 - 1667

Опубликована: Фев. 10, 2025

Background: Ovarian cancer (OC) and cervical (CC) are the leading causes of death among women. Therefore, identifying markers for early detection treatment is critical. CDK1 governs G2/M transition cell cycle a significant regulatory protein cycle. RO-3306 UBE2C related to expression might jointly facilitate development OC. CDK2 phosphorylate MLK3, which plays an important role in invasion proliferation OC cells. Furthermore, miR-490-3P targets restrains growth ovarian tumors. also crucial part progression CC. For instance, overexpression can rescue effect RCC1 knockdown, involved key processes, such as cytoplasmic transport, on G1 progression. Using bioinformatics analysis, we evaluated functional enrichment co-expressed gene these two cancers its impact their prognoses. Methods: First, screened public datasets OC- CC-associated DEGs identified intersecting genes. Enrichment analyses genes revealed biological pathways processes. We then generated protein-protein interaction networks identify central modules. Results: Additional that regulation germ maturation were primary processes regulated by core examined function CC, demonstrating association with particular immunological infiltration patterns. mutational burden, copy number variation, patient survival indicated may be useful prognostic marker. Finally, immunohistochemical examination confirmed some candidate clinical samples. Conclusion: These findings shed light molecular CC will aid identification novel future research regarding cancers, including diagnosis treatment.

Язык: Английский

Процитировано

0
Battlegrounds of treatment resistance: decoding the tumor microenvironment DOI
Mobina Bayat, Javid Sadri Nahand

Naunyn-Schmiedeberg s Archives of Pharmacology, Год журнала: 2025, Номер unknown

Опубликована: Март 25, 2025

Язык: Английский

Процитировано

0
Remodeling of tumor microenvironment by cellular senescence and immunosenescence in cervical cancer DOI

Yijiang He,

Yue Qiu,

Xiansong Yang

и другие.

Seminars in Cancer Biology, Год журнала: 2024, Номер 108, С. 17 - 32

Опубликована: Ноя. 23, 2024

Язык: Английский

Процитировано

0
Research progress of immune checkpoint inhibitors in ovarian cancer DOI Creative Commons

Lingli Zhao,

Yanhong Zhai,

Gaoli Niu

и другие.

Exploration of Immunology, Год журнала: 2024, Номер unknown, С. 853 - 870

Опубликована: Дек. 18, 2024

Ovarian cancer is the deadliest malignant tumor in female reproductive system. Despite advancements standard treatments such as debulking surgery and platinum-based chemotherapy, overall survival rate remains low. The emergence of targeted therapies, including Poly(ADP-ribose) polymerase (PARP) inhibitors anti-angiogenic agents, has provided new avenues for treatment. However, drug resistance disease heterogeneity continue to pose significant challenges. Immune checkpoint (ICIs), an emerging therapeutic approach, primarily target programmed cell death protein 1 (PD-1)/programmed ligand (PD-L1) cytotoxic T-lymphocyte antigen 4 (CTLA-4) pathways restore anti-tumor immune responses. Although ICIs have shown efficacy other malignancies, their effectiveness ovarian limited, with a response only 10–15% monotherapy. Recent studies focused on combining or PARP enhance outcomes. This article reviews progress cancer, monotherapy combination treatment strategies, explores targets strategies aimed at improving patient prognosis achieving personalized By gaining deeper understanding microenvironment its evasion mechanisms, there hope developing more effective options future, ultimately rates quality life patients.

Язык: Английский

Процитировано

0